Tourmaline Bio
TRML
TRML was delisted on the 27th of October, 2025.
53 hedge funds and large institutions have $27.5M invested in Tourmaline Bio in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 12 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.14% less ownership
Funds ownership: 65.46% → 64.32% (-1.1%)
5% less funds holding
Funds holding: 56 → 53 (-3)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
62% less capital invested
Capital invested by funds: $72.2M → $27.5M (-$44.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.38M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$246K |
| 3 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$128K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$114K |
| 5 |
Two Sigma Investments
New York
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.43M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.19M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$521K |
| 4 |
ACM
Aisling Capital Management
New York
|
-$460K |
| 5 |
CCM
CAAS Capital Management
New York
|
-$333K |
TRML Hedge Fund Activity: Q4 2022 in Review
53 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Tourmaline Bio (TRML) for Q4 2022, worth a combined $27.5M — down 62% from $72.2M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of TRML and 10 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 17 added.
The largest buyer was Citadel Advisors, adding an estimated $1.38M. The largest seller was BlackRock, cutting an estimated $1.43M.
- 53 institutional investors held Tourmaline Bio (TRML) as of Q4 2022, down from 56 in Q3 2022.
- Funds reported $27.5M of Tourmaline Bio stock for Q4 2022, down 62% quarter-over-quarter.
- 10 funds opened new Tourmaline Bio positions in Q4 2022 and 12 closed out, a net change of -2 holders.
- The largest Tourmaline Bio buyer in Q4 2022 was Citadel Advisors, an estimated $1.38M added.
- The largest Tourmaline Bio seller in Q4 2022 was BlackRock, an estimated $1.43M sold.
Based on aggregated 13F filings for Q4 2022.